Latest News and Press Releases

Second antibody-drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibodyPreclinical results demonstrate strong anti-tumor activity and...

VANCOUVER, British Columbia, July 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical...

Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodiesLong-term outcomes and survival data for Ziihera® (zanidatamab-hrii),...

VANCOUVER, British Columbia, May 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

Company’s first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways critical in respiratory inflammationNovel...

Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentReported $321.6 million in cash...

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission...

VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...